Get the Stockscreener App
45.04
0.24%
+0.11
After Hours:
45.04
Merus N.V stock is currently priced at $45.04, with a 24-hour trading volume of 822.96K.
It has seen a +0.24% increased in the last 24 hours and a +0.29% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $43.90 pivot point. If it approaches the $46.69 resistance level, significant changes may occur.
Previous Close:
$44.93
Open:
$44.66
24h Volume:
822.96K
Market Cap:
$2.64B
Revenue:
$43.95M
Net Income/Loss:
$-154.94M
P/E Ratio:
-11.98
EPS:
-3.76
Net Cash Flow:
$-146.19M
1W Performance:
+13.14%
1M Performance:
+0.29%
6M Performance:
+119.60%
1Y Performance:
+127.36%
1D Range:
$44.00
$45.84
52W Range:
$18.21
$52.03
Merus N.V Stock (MRUS) Company Profile
Name
Merus N.V
Sector
Industry
Phone
31 30 253 8800
Address
Yalelaan 62, Utrecht
Merus N.V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N.V Stock (MRUS) Latest News
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Zacks Investment Research
Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO
GlobeNewswire Inc.
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
GlobeNewswire Inc.
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
GlobeNewswire Inc.
Merus participera à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare
GlobeNewswire Inc.
Merus N.V Stock (MRUS) Financials Data
Merus N.V (MRUS) Revenue 2024
MRUS reported a revenue (TTM) of $43.95 million for the quarter ending December 31, 2023, a +5.68% rise year-over-year.
Merus N.V (MRUS) Net Income 2024
MRUS net income (TTM) was -$154.94 million for the quarter ending December 31, 2023, a -18.10% decrease year-over-year.
Merus N.V (MRUS) Cash Flow 2024
MRUS recorded a free cash flow (TTM) of -$146.19 million for the quarter ending December 31, 2023, a +7.20% increase year-over-year.
Merus N.V (MRUS) Earnings per Share 2024
MRUS earnings per share (TTM) was -$3.04 for the quarter ending December 31, 2023, a -4.83% decline year-over-year.
Merus N.V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Dec 15 '23 |
Sale |
25.00 |
22,386 |
559,650 |
0 |
| Shuman Harry | VP Controller, PAO |
Dec 08 '23 |
Sale |
24.44 |
250 |
6,110 |
7,117 |
| Shuman Harry | VP Controller, PAO |
Dec 01 '23 |
Option Exercise |
0.00 |
2,500 |
0 |
7,942 |
| Shuman Harry | VP Controller, PAO |
Dec 01 '23 |
Sale |
24.58 |
575 |
14,133 |
7,367 |
| Shuman Harry | VP Controller, PAO |
Jun 01 '23 |
Option Exercise |
0.00 |
2,500 |
0 |
6,017 |
| Shuman Harry | VP Controller, PAO |
Jun 01 '23 |
Sale |
21.48 |
575 |
12,351 |
5,442 |
About Merus N.V
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
1.53%
3.38%
Cap:
|
Volume (24h):